ANGPTL3 acts as dual inhibitor of lipoprotein lipase and endothelial lipase, thereby increasing plasma NEFA, triacylglycerols, LDL-cholesterol and HDL-cholesterol, and its plasma concentration is associated with clinical/histological markers of NAFLD/NASH and with hepatic ANGPTL3 expression [122]. This evidence concerns the gene ANGPTL3 and metabolic dysfunction-associated steatohepatitis.